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Abstract
Background. The Center for Transfusion Medicine, Cell Therapy and
Cryobiology, Milan, Northern Italy, is the headquarter of the POLI-MI
biobank. It co-ordinates the biobank activities of the Fondazione Ca’
Granda Ospedale Maggiore Policlinico of Milan. Such activities require
specific safeguarding of donors’ rights and protection of sensitive and
genetic data. The Fondazione Ca’ Granda Ospedale Maggiore
Policlinico has set up a project on informed consent with the aim of
developing awareness and understanding of this issue. Within this
project, it has been decided to evaluate how consent for biobanking
material is expressed. 
Design and methods. The aim of the study was to evaluate the qual-
ity and completeness of consent to biobanking in the POLI-MI biobank.
This was a retrospective study carried out in 2012 on samples of con-
sent declarations collected by biobank units in 2011. Some units used
a single, standard consent model available from a previous POLI-MI
biobank workgroup. Other units used models which had been previ-
ouly formulated. Evaluation was made using a form that indicated the
essential elements of consent.
Results. A total of 48 consent declarations were collected using the
single, standard model and 84 were collected using other models. The
consent declarations that used the single, standard model were found
to be the most complete and were filled in better than other models.
Conclusions. Progressive adoption of a simple, standard consent
model is expected to improve the quality of consent acquisition.
Regular audit of the compliance of consent practices with ethical and
legal requirements is mandatory to improve the quality of research
biobanking.
Introduction
Biobanks collect and store human and non-human biological mate-
rials for diagnostic and research purposes. Some countries have iden-
tified their ideal operative context to be within institutes known as
Biological Resource Centers (BRC).1,2 
The creation of biobanks has required, among the various critical
issues involved, the definition of adequate privacy protection systems
to safeguard donors. In fact, biobanks collect and hold sensitive data
and biological samples also for long periods of time. These can be used
for research purposes even many years after their collection.
Furthermore, since biobanks often operate through the internet, bio-
logical samples and their related data are often used for multicenter
studies and can even be exchanged between BRCs in different coun-
tries.3 There is little homogeneity in the legislation regulating the
exchange of biological materials and their documentation between
countries. For example, even within the European Union there is no
shared regulatory system concerning biobanking. This means that the
same kind of activity is allowed in some Member States but not in oth-
ers.4 For this reason, some countries are starting to standardize their
legislation and to share regulations concerning research and working
methods.5-9 Between 1999 and 2001, the European Commission set up
the EUROGENEBANK, a project which involved six countries and
aimed to define the types of existing biobanks and the critical issues
related to their regulation. This has opened the debate on several
issues, such as the methods used to collect biological samples, the
objectives of biobanking, how the samples and related data should be
managed and the access procedures.4 In 2009, the German BMB-EU
Coop project analyzed the legal and ethical consequences of interna-
tional biobanking, underlining how similar theoretical principles are
applied in different ways in different countries.10 One of the aspects to
which legislators should pay attention is the issue of consent. The
American Society of Human Genetics (ASHG) has identified some
essential items that must be covered by the donor’s consent declara-
tion for collecting samples for a specific research project: i) the objec-
tive of the research, ii) the limitations and possible consequences, iii)
risks and benefits, iv) the type of information expected from the
research, v) how results will be made available, vi) methods of main-
taining confidentiality. According to the ASHG, it is unacceptable to
request informed consent for any possible research carried out using
the samples at a later date. In cases of deceased donors, the indiscrim-
inate use of samples and data is not allowed, since this could put rela-
tives at risk.11
Italian law concerning the donation of biological materials and
treatment of personal data is presented in legislative decrees.12-17
Significance for public health
Biobanks collect and store human and non-human biological material for
diagnostic and research purposes. These biobanks keep sensitive data and
biological samples also for long periods of time, and such data and samples
can be used for research even many years after they have been deposited.
Therefore, a well-designed and carefully applied informed consent is an
essential document to help research purposes. There has been a continuous
growth in the activities of the biobanks yet a definitive informed consent
model is still not available. So, it is important i) to make a systematic evalu-
ation of the models of consent used, and this should also include a survey of
public opinion in order to develop guidelines which can be shared in an
international setting and ii) to improve the quality of research projects.
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The Legislative Decree n. 196 of 30th June 2003 (Code for the protec-
tion of personal data) guarantees […] that the treatment of personal
data is carried out with respect for the fundamental rights and liberties,
and the dignity of the person concerned, with particular reference to
confidentiality, personal identity and personal data protection rights.12
The Legislative Decree n. 191 of 6th November 2007 (bringing into
force of the 2004 EC directive 2004/23/EC on the definition of the regu-
lations concerning donation quality and safety, the supply, control, pro-
cessing, preservation, storing and distribution of human tissues and
cells) lists the essential information that must be given to donors, […]
that is the objective and nature of the supply, its consequences and risks,
analytical tests (if carried out), registration and protection of donor
data, medical confidentiality, therapeutic objective and potential bene-
fits, together with information on guarantees that can be given to safe-
guard the donor.13 In order to validate the consent documentation,
there is some essential information that the donor must receive.
Guidelines regarding this information have been published on the
Official Journal n. 159 of 11th July 2011.9 Recently, Lombardy Region
has developed guidelines for the correct institution and regulation of
biobanks, suggesting a possible organizational model and emphasizing
the importance of the informed consent; however, operative instruc-
tions are not provided.17
The problems involved in informed consent were also examined at
the POLI-MI biobank of the Fondazione Ca’ Granda Ospedale Maggiore
Policlinico of Milan. This is part of the Center for Transfusion
Medicine, Cell Therapy and Cryobiology. The POLI-MI biobank offers a
service of cryopreservation of biological material collected for research
purposes by all the Departments in which the Fondazione is divided,
the Operative Units (OU). 
The Center for Transfusion Medicine, Cell Therapy and Cryobiology
is made up of 4 sectors:
i) The Milano Cord Blood Bank which performs characterization,
storage and distribution of placental blood for hemopoietic trans-
plantation; the Cell Manipulation Laboratory is responsible for the
cryopreservation of hemopoietic stem cells from peripheral blood
and bone marrow.
ii) The Franco Calori Cell Factory, which is a certified laboratory com-
pliant to the regulations and standards of Good Manufacturing
Practices (GMP). It is authorized to produce cell therapy products,
and to carry out translational research on stem cells for transplan-
tation and tissue repair.
iii) The Interdepartmental Flow Cytometry Center carries out research
and services for cell immunophenotyping and sorting; the
Experimental Hepatology Laboratory studies cancer stem cells.
iv) The POLI-MI Biobank preserves around 100,000 human biological
samples (serum, plasma, cells, DNA, tissue) collected for research
purposes from 24 internal and external groups.
In 2005, the Fondazione set up a workgroup with the aim of revising
the methods of attaining informed consent relating to biological sam-
ples collected for research purposes on the basis of the Italian legisla-
tion in force and in consideration of the international experiences
reported so far.
The evaluation of the consent documentation used by the
Fondazione identified a variety of models. On the basis of the models
in use, and taking into account the requirements reported in the liter-
ature, the workgroup drew up a single, standard model.18 This model
was proposed to all OU of the Fondazione and was used experimental-
ly from 2009 to 2011. This model was formally adopted by the
Fondazione on 22nd November 2011.Research objective
Since the immediate adoption of the new model by all OU in the
Fondazione who use the biobank services is unlikely, through 2011 it
was decided to carry out a survey to evaluate its use by the various OUs
and at the same time to verify the completeness and the correct compi-
lation of the old models that may still be in use.
All original consent documents collected at the Fondazione are
archived in the patient’s case sheet. The physician in charge provides
the patient with information about the collection, preservation and use
of human biological materials for research and obtains the patient’s
consent. The physician presenting the consent form to the patient is
responsible for its correct compilation in all its parts.
Design and methods
The REXIC project is a retrospective study that aims to verify the
adoption of the single, standard consent model proposed for experi-
mental use in 2009, and to check the correct compilation and archiving
of the informed consent documentation relating to biological samples
deposited in the bank during 2011.
The study protocol was drawn up together with the directors and
staff of the Center for Transfusion Medicine, Cell Therapy and
Cryobiology (CTMC) and the Post-graduate School of Hygiene and
Preventive Medicine in Milan. For the study, we selected the OUs or
sectors which sent samples to the POLI-MI biobank during 2011. All
consent documentation was examined by those OUs or sectors that col-
lected at least 50 samples; otherwise a 10% random sample of docu-
ments was examined.
In order to collect data relating to the completeness and correct com-
pilation of the consent documentation, an ad hoc evaluation form was
provided based on the single, standard consent model proposed by the
CTMC and established in November 2011. Researchers confirmed the
OU (or sector) on the form and a number code was used to identify the
type of consent examined if this was not already identified by a quality
control system code assigned by the Fondazione. The form included
various items subdivided into sections. The researcher had to verify
whether each of these issues had been filled in and whether compila-
tion was correct and/or complete. 
In the first section we checked the presence of information relating
to the OU where the samples were taken and its contact details (tele-
phone number and e-mail address).
This information is useful for the accountability of donors.
In the second section we verified the presence of 5 items: i) the rea-
sons why and the methods by which the sample was taken; ii) informa-
tion on the methods of preservation used for the biological samples; iii)
information on the management of the documentation related to the
samples deposited in the bank (e.g. results of tests carried out, sensi-
tive donor data, etc.); iv) information on the risks related to the collec-
tion and preservation of the biological material; v) information on the
disposal of the stored material.
This kind of information is needed to justify the type of the collected
sample and to explain the aim of the research. We also examined
whether the consent documentation included a note confirming that
the donor may, at any time, withdraw consent to the use of his/her sam-
ples and data by writing to the Director of the OU where the samples
were taken, and if collected data were treated with the needed confi-
dentiality and in respect of the donor’s privacy.
Lastly, the protocol set out the expression of consent for: i) addition-
al sample collection; ii) the preservation of samples; iii) the manipula-
tion of biological material; iv) the management of sensitive data; v) the
sharing of anonymous data; vi) the use of data for scientific publica-
tion; vii) the possible use of samples and data for further research; viii)
the disposal of the samples once the research has been completed.
The collection of consent for future research is fundamental since
the use of biological materials is not always immediate, and samples
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can be stored for an undefined time. Each consent document was
checked to evaluate whether the following data had been provided:
date, name, surname and signature of the person responsible for
obtaining consent and of the donor. For those OUs which had still not
adopted the single, standard model, evaluation of consent was made
through a comprehensive checklist of all the above-listed items.
The project was presented by the Directors of the involved OUs dur-
ing several meetings and in the presence of a specialist in Public
Health and post-graduate Public Health students, who had been previ-
ously instructed on to how to fill in the evaluation form and who subse-
quently checked the consent documentation. 
The Public Health specialist and 4 students were asked to verify
whether the patients’ case sheets contained the consent documenta-
tion; they also had to report the type of consent model used and to eval-
uate whether it had been filled in correctly and fully by those responsi-
ble for obtaining the patient consent. A pilot evaluation was made on 10
patient case sheets at one of the OUs, where the single, standard con-
sent documentation adopted in November 2011 was already in use to
test the evaluation method and to examine the level of agreement
between the researchers. The same 10 patient case sheets were evalu-
ated separately by all the researchers and the results were then com-
pared in order to establish if the level of agreement was acceptable. A
level of agreement of over 95% was considered sufficient to then assign
2 researchers to each OU for subsequent evaluation of the patient case
sheets: the 10 case sheets and consent forms obtained the same evalu-
ation from all the researchers of the examination group.
Results
A total of 172 patient case sheets were examined (Table 1). Consent
documentation was included in 132 (76.7%) cases. In the remaining 40
(23.3%) patient case sheets, the absence of any consent documenta-
tion meant that no evaluation of content could be made. Two OUs
adopted the single, standard consent model: OU1 and OU2. 
The researchers identified that 48 consent declarations were
obtained using the single, standard model adopted in November 2011
and other 84 consent documents were obtained using other models.
The consent declarations, obtained using the single, standard model
were shown to be the most complete and were filled in better than the
other models used. In fact, the standard consent model always includ-
ed information relating to the OU and the physician responsible for
obtaining consent while the other items were filled in in 85-90% of
cases. The missing items were: use of the information for scientific
publication and possible sharing of data acquired anonymously from
other research centers. Furthermore, items relating to taking addition-
al samples and their preservation were only included in less than 20%
of the consent documents. Finally, 7 consent documents were not
signed and/or the date was missing (Table 2).
As far as the 84 consent documents obtained using other models are
concerned, only items relating to the reason for the sample collection and
the use of material for research were nearly always included and filled in
fully and correctly (95% and 98% of cases, respectively). Compilation of
items relating to consent for the sample to be taken was also satisfacto-
ry (99%), while consent to sample preservation and data availability was
compiled in 64% of cases. Compilation of other sections was missing or
incomplete. Some types of consent models had sections that were pre-
printed and were, therefore, already filled in, such as information relat-
ing to the physician responsible for obtaining consent (Table 3). Finally,
it should be noted that examination of the patient case sheets and, there-
fore, evaluation of the consent were carried out directly at each individ-
ual OU. This allowed researchers to meet those responsible for obtaining
consent in person. This provided an opportunity to meet the staff
involved and to raise their awareness as to how important it is to correct-
ly and fully fill in and archive the documentation.
Discussion
Before discussing the results of our study, we feel appropriate to
point out its main limitations, due to the relatively limited number of
forms that could be examined. In this regard, it was disappointing to
note that, independently from the type of informed consent form, in
several instances the form was missing or partially filled. However,
although disappointing and negative in its nature, this finding is itself
an interesting result of our investigation, which stresses the impor-
tance of regular staff education and careful auditing of informed con-
sent practices related to the collection of biological materials for
research biobanking. In spite of the above limitations, an analysis of
the results shows that the adoption of the single, standard consent
model improved the quality of consent collection. The only information
missing from this type of consent model was the expression of consent,
while the items relating to taking and preserving additional samples
was included in only 20% of cases. Given the retrospective nature of the
study, it was not possible to clarify whether in the majority of cases
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Table 1. Number of patient case sheets examined at the Operative
Units selected for the study.
Operative unit Case sheets examined 
1 40
2 45
3 19
4 28
5 40
Table 2. Results of checklist of the standard consent model.
Item Included Incomplete Not included
n. (%) n. n.
Operative units and 48 (100) 0 0
contact details
Physician responsible 41 (85) 7 0
for obtaining consent 
Reason for sample collection 46 (96) 2 0
Information on sample collection 46 (96) 2 0
Use of the information 18 (37) 30 0
Risks 46 (96) 2 0
Disposal 45 (94) 3 0
Sample collection 8 (17) 0 40
Preservation 7 (14) 1 40
Use of materials for research 46 (96) 2 0
Management of sensitive data 46 (96) 2 0
Sharing of anonymous data 46 (96) 2 0
Use for publication 46 (96) 2 0
Use for research and development 7 (14) 1 40
Disposal 46 (96) 2 0
Date, signature, name and surname 41 (85) 7 0
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these items were missing because they were not relevant and this will
be discussed with the OUs involved. However, critical issues still
remain and it is hoped that these problems will gradually be resolved by
more OUs adopting and using this standard model, and by its subse-
quent revision and improvement. 
The model currently being used was drawn up on the basis of the
European Masters in Bioethics. Over the last decades, questions have
been raised concerning which type of informed consent should be con-
sidered the gold standard from an ethical point of view, and this is of
particular concern in fields such as biobanking. Some authors empha-
size that consent to biobanking can never cover everything and can not,
therefore, be informed. This is because at the moment in which con-
sent is obtained, it is probably not known for what type of future
research the data will be used. It is, therefore, often impossible to
inform the donor as to the detailed objectives, methodology, risks and
financial sources of subsequent research. One example of a good orga-
nizational model is provided by the United Kingdom Biobank that has
been set up in such a way as to offer an important resource capable of
sustaining a wide range of research aimed at the prevention, diagnosis
and treatment of diseases and promotion of health issues across all
social groups. This biobank uses a consent model that is fairly general
in format. The biobank does, however, encourage much greater partic-
ipation on the part of donors in its operations, also through the cre-
ation of a specific interactive website.19 Another question, which is
often discussed in the scientific community, is the possibility of having
the patient consent model renewed each time it is proposed that the
preserved samples are used for a new research project. There is a gen-
eral agreement on the fact that blank consent is not acceptable, even
though this is still used in some centers. In many cases, the option of
asking consent for a wider use of material and data although providing
little specific information on the project is being considered. This
allows the researcher to carry out a wide range of activities but the con-
sent is too vague to be considered informed.20,21
Various institutions are wondering how to draw up a consent model
that respects those issues identified as essential. It is interesting to
mention the experience of the S. Giovanni di Dio Center in Brescia,
Northern Italy. Here they have revised the main criteria related to the
preservation and use of human-derived material from an ethical point
of view; sixteen critical areas were identified that must be respected by
the consenting individual.22 These regard the type of material taken,
the location and duration of preservation, the reasons for the biobank-
ing, the consequences on donor health, the voluntary nature of the
donation, donor privacy, control of access to the deposited material and
any possible transfer.
Conclusions
Defining the requirements for giving consent to the collection, stor-
age and use of biological samples and related information for research
is still a subject of controversy at international level.18 Samples pre-
served in biobanks represent an important resource for future
research, but their use can raise ethical questions regarding the con-
sent obtained.23,24 Some groups are developing regulatory systems for
the biobanks using a self-administered questionnaire to evaluate the
attitudes and perceptions of potential donors of biological samples; the
majority of those interviewed have shown a positive attitude towards
genetic research.18 In spite of rapid expansion of the biobanks and
their related activities, a definitive consent model is still not available.
This can probably be achieved by modifying and adapting the models in
current use and by taking into consideration the perceptions and atti-
tudes of donors. Indeed, general population’s confidence in research is
essential in order to achieve important benefits for society at large. It
is to be hoped, therefore, that other experiences of this type are report-
ed in the literature by those who are involved with ethical, legal and
social issues related to research biobanking. It can be expected that
larger studies could provide useful information to improve the quality
of current practices of research biobanking.
Recently, critical aspects of the above issues have been thoroughly
discussed in an editorial on HeLa and WI-38 cells recently published in
Nature, that invites for a rethinking of the ethical issues concerning
the use of human tissue in research.25
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Table 3. Results of the checklist of other consent models.
Item Included Incomplete Not included
n. (%) n. n.
Operative units and contact details 65 (77) 0 19
Physician responsible 29 (35) 41 14
for obtaining consent
Reason for sample collection 80 (95) 1 3
Information on sample collection 51 (61) 1 32
Use of the information 51 (61) 1 32
Risks 36 (43) 0 48
Disposal 0 (0) 36 48
Sample collection 83 (99) 1 0 
Preservation 54 (64) 1 29
Use of materials for research 82 (98) 2 0 
Management of sensitive data 51 (61) 1 32
Sharing of anonymous data 51 (61) 1 32
Use for publication 1 (1) 1 82
Disposal 0 (0) 0 84
Date, signature, name and surname 34 (40) 50 0 
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